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Abstract
Background: BCG immunogenicity in infants differs between populations and these differences have been
attributed to various factors. In this study, the influence of geographical location, season of birth, timing of
vaccination, micronutrient status (zinc) and inflammatory status (C-reactive protein, CRP) were assessed.
Methods: Immunogenicity was assessed by cytokine signature in culture supernatants from diluted whole blood
samples stimulated with M. tuberculosis PPD, using a multiplex bead assay. Results were correlated with the plasma
zinc and CRP concentrations at the time of sampling, and with interview and household data. BCG vaccinated
infants were recruited in Malawi, The Gambia and the UK.
Results: In Malawi, infants vaccinated within the first week after birth showed lower production of most cytokines
measured than those vaccinated later. The number of cytokines showing significant differences between Malawian
and Gambian infants decreased after adjusting for season of birth. In Malawi, a proportion of infants had zinc
deficiency and elevated plasma CRP (>10 mg/L), but neither zinc deficiency nor high CRP was associated with
production of any of the cytokines measured.
Conclusions: The cytokine/chemokine signatures observed in response to M. tuberculosis PPD in infants at
3 months post BCG vaccination were affected by geographical location, season of birth, and timing of vaccination
but not associated with the concentration of plasma zinc or inflammatory status. These factors should be
considered in future trials of new TB vaccines.
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Background
Tuberculosis (TB) is caused by Mycobacterium tubercu-
losis (M. tb) and is one of the major global health chal-
lenges with 8.6 million incident cases worldwide [1].
Despite successful global TB control efforts and decreas-
ing TB incidence [1], the variable efficacy and immuno-
genicity of the BCG vaccine in different populations
[2-4] highlights the ongoing need to develop new vac-
cines or delivery strategies. Better understanding of the
factors leading to variations in immune responses to
BCG and how different immune responses correlate
with the efficacy of BCG, may help to evaluate the effi-
cacy of new TB vaccines.
Micronutrient deficiencies may impact on this im-
mune response. Zinc has been classified by WHO as a
“problem” micronutrient which requires supplementary
provision to breast-milk fed infants from about 6 months
of age [5]. Zinc deficiency causes an imbalance in im-
mune function by shifting a Th1 to a Th2 response,
which results in cell-mediated immune dysfunction that
may increase susceptibility to various pathogens [6].
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There have been reports showing the beneficial effect of
zinc supplementation on the incidence of infectious dis-
eases [7,8]. The best available biomarker to assess popu-
lation zinc status is serum or plasma zinc concentration
[9]. Zinc deficiency may occur as a result of inadequate
dietary intake [10]. In Malawi, the most important food
staple is maize and a maize porridge called nsima which
has a high concentration of phytate. Phytate inhibits bio-
availability of zinc [11] and may cause zinc deficiency,
which may be exacerbated by limited animal protein in-
take in rural areas.
Inflammation, as a result of infection, may also influ-
ence the immune response following vaccination. C-
reactive protein (CRP) is an acute phase protein which is
released from the liver. It exists normally in trace levels
in serum and rapidly increases in response to a variety
of infections and inflammatory conditions [12]. Quanti-
tative CRP concentration in plasma or serum has been
used as a screening tool for bacterial and viral infection
[13]; a range of 10–40 mg/L occurring in mild inflam-
mation and viral infection, while a range of 40–200 mg/
L is observed in active inflammation and bacterial infec-
tion [12]. CRP is also measured to help interpret the re-
sults of zinc assays as the concentration of serum zinc
varies according to inflammation status [9].
Previous immunology studies undertaken at the
Karonga Prevention Study (KPS) to compare the im-
mune responses between Malawi and the UK, following
BCG vaccination, showed different IFN-γ responses to
mycobacterial antigens in adolescents and infants in
these two populations. This was regardless of the extent
of exposure to environmental mycobacteria, which has
been the dominant hypothesis for interpreting variability
in BCG vaccine-induced protection [4,14,15]. These re-
sults led us to investigate other potential factors which
may influence infant immune responses to mycobacterial
antigens. In this study, we looked at the cytokine/che-
mokine signatures in infants at 3 months post BCG vac-
cination. To assess the effects of geographical location
and the environment, infants born in different seasons
in Malawi and The Gambia were examined. The latitude
of the study sites, Karonga in Malawi, Sukuta in The
Gambia and London in the UK are 10°S, 13°N and 51°N
respectively, and it was hypothesized that the geograph-
ical similarities between Malawi and The Gambia might
lead to cytokine/chemokine signatures that would be
more similar to each other compared to the UK. Fur-
thermore, the effect of vaccination timing on the cyto-
kine/chemokine signatures in Malawian infants was
examined. Finally, we determined the micronutrient sta-
tus and degree of inflammation by measuring the con-
centrations of plasma zinc and CRP in Malawian infants.
Our previous findings showing higher Th2 and lower
Th1 responses to M. tb purified protein derivative (PPD)
in Malawian infants compared with UK infants [4,14,15],
led us to examine zinc deficiency in Malawian infants
based on the reports regarding a Th1 to Th2 cytokine
shift in zinc deficiency and the effects of high concentra-
tions of phytate in maize on zinc concentrations [6-8].
In addition, the associations between plasma zinc and
CRP concentrations and cytokine responses to M. tb
PPD were analysed.
Methods
Sample and data collection
Samples from studies assessing immune responses fol-
lowing BCG vaccination in infants from Malawi [4,16],
The Gambia [17] and data from a parallel study in the
UK [4,18] were included in this study. The samples col-
lected from infants at 3 months post BCG vaccination at
all study sites were stored at −80°C until assayed to de-
termine cytokine/chemokine signatures and concentra-
tions of plasma zinc and CRP.
Infants were vaccinated with BCG within the first
week of life in Malawi (Danish strain 1331, 0.05 mL,
intradermal injection; Statens Serum Institut) [4,16] and
The Gambia (BCG-Russia, Lot 037G9105, 0.05 mL,
intradermal injection; Serum Institute India) [17]. At
3 months post BCG vaccination, the infants were re-
cruited and a diluted whole blood assay (WBA) was per-
formed with M. tb PPD (5 μg/mL), PHA (5 μg/mL) and
the control (RPMI medium only) to examine the IFN-γ
response to mycobacterial antigens [16,17]. For the
multiplex bead assay, culture supernatant samples were
tested from 30 Malawian infants and 24 Gambian infants
(Table 1). For the comparison of cytokine responses to
M. tb PPD, the cytokine response data from UK infants
from a previous study of post BCG immune responses
were used [18]. The BCG vaccine strain used in the UK
was the same as in Malawi (BCG-Danish 1331) and the
median age of UK infants tested at 3 months post BCG
vaccination was 7 weeks at the time of vaccination. The
same protocols, including the concentration of antigens,
were used for WBA in the Malawian, UK and Gambian
cohorts [4,17].
In Malawi, 63 plasma samples from the infants at 3
months post BCG vaccination were tested for plasma zinc
and CRP. Among the 403 infants vaccinated within the first
week of life [16], those who showed high IFN-γ (> 50 pg/
mL) in control cultures (n = 133) and whose mothers had
HIV, malaria or helminth infection (n = 165) were ex-
cluded. To control confounding factors for the zinc assay,
only breast-milk fed infants were included and diurnal vari-
ation was avoided by using samples collected in the
morning (n = 105). In total, 63 samples from 27 males and
36 females were available (Table 1). As CRP levels are ele-
vated after immunization with vaccines such as DPT (diph-
theria, pertussis, tetanus), Haemophilus influenzae b (Hib),
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hepatitis B (HBV) and inactive polio vaccines (IPV) [19], in-
fants who had other immunisations in the 7 days prior to
blood collection were excluded from the CRP data analysis.
Ethical approval for the studies was obtained from the
London School of Hygiene & Tropical Medicine Ethics
Committee, the National Health Sciences Research
Committee in Malawi and the Gambian Government/
Medical Research Council (MRC) Joint Ethics Commit-
tee; permission to export samples was granted by
the National Health Sciences Research Committee in
Malawi and by the Gambian Government/MRC Joint
Ethics Committee in The Gambia.
Multiplex bead assay
Concentrations of 42 cytokines and chemokines: IL-1α,
IL-1ra, IL-1β, IL-2, sIL-2Rα, IL-4, IL-5, IL-6, IL-9, IL-10,
IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IFN-α2, IFN-γ,
TNF-α, TNF-β, sCD40L, MIP-1α (CCL3), MIP-1β (CCL4),
Gro-α (CXCL1), IL-8 (CXCL8), IP-10 (CXCL10), MCP-1
(CCL2), MCP-3 (CCL7), MDC (CCL22), TGF-α, G-CSF,
GM-CSF, IL-3, IL-7, Eotaxin, FGF-2, Flt-3 L, Fractalkine
(CX3CL1), EGF, VEGF, PDGF-AA, PDGF-AB/BB and
RANTES (CCL5) were determined in culture supernatant
samples obtained from 30 Malawian and 24 Gambian in-
fants. Multiplex beads were diluted 1 in 2 in bead diluent
and the 42plex bead assay was performed according to
the manufacturer’s protocol (no. MPXHCYTO60KPMX42;
MILLIPLEX®MAP Kit, Millipore, Billerica, MA, USA) as de-
scribed previously [18]. Multiplex quantification of cyto-
kines in all samples was performed using the Luminex R
100 System (Luminex, Austin, TX, USA).
The same protocol for the 42 multiplex bead assays
was used for testing all samples, although the assays
were performed at different times. The antibodies for all
42 cytokines in all the kits used (no. MPXHCY-
TO60KPMX42; MILLIPLEX®MAP Kit) were derived from
the same clones. Samples from both Malawi and The
Gambia were transported to LSHTM for testing.
Zinc colorimetric assay
Zinc concentration was measured in 63 Malawian infant
plasma samples by a zinc colorimetric method. A Quanti-
Chrom™ zinc assay kit (BioAssay Systems, Hayward, CA,
USA) was used according to the manufacturer’s protocol.
Briefly, 100 μL of 5 standards (10.0, 7.5, 5.0, 2.5 and 0 μM
of Zn2+), 50 μL of diluted plasma samples (1:5) and sample
blanks (50 μL sample + 2 μL EDTA) were transferred into
the wells of a clear flat-bottom 96 well plate and 200 μL of
working solution (200 μl of “reagent A” and 4 μl of each
“reagent B” and “reagent C”) was added. After incubation
for 30 minutes at room temperature, optical density was
measured at 425 nm using a Spectramax M3 plate reader
(Molecular Devices, Sunnyvale, CA, USA).
CRP test
Plasma CRP concentrations were measured by sandwich
ELISA using human anti-CRP IgG (THE BINDING SITE,
Birmingham, UK; 1:4000), HRP-conjugated anti-human
CRP protein (DAKO, Carpinteria, CA, USA; 1:1000) and
human CRP standard serum (Behring, Haywards Heath,
UK). Plasma samples were diluted 1:200. Substrate solution
was prepared by adding 500 μL of 10 mg 3,3′,5,5′-tetra-
methylbenzidine dissolved in DMSO (Sigma-Aldrich) into
the 50 mL of substrate buffer (10 mL of 0.1 M citric acid
and 10 mL of 0.2 M Na2HPO4; pH 4.5 with 10 μL H2O2;
30%; Sigma-Aldrich). Plates were read at 450 nm with a ref-
erence wavelength of 490 nm using a Dynal plate reader
(DYNEX Technologies, Worthing, UK).
Statistical analysis
The Mann Whitney test was used to compare the cyto-
kine/chemokine signatures between two groups from
Table 1 Samples utilised for the assays
Malawi The gambia Purpose of collection
Culture supernatant 30 24 42plex bead assay
Season of birth Rainy season 16 0
Dry season 14 24
Plasma 63 (57) Zn2+ & CRP assay
Season of birth Rainy season 40 (38)
Dry season 23 (19)
BCG given time (week after birth) 1 1
Mean Age at test (month) 3.2 (2.8-6.5) 3.1 (1.8-3.8)
Mean body weight at test (kg) 6.3 (4.4-9.2) 6.2 (4.2-7.7)
Culture supernatants obtained from Malawian (n = 30) and Gambian infants (n = 24) tested at 3 months post BCG vaccination were utilised to measure 42
cytokine/chemokine signatures. In Malawi, the rainy season is from January to May and the dry season is from June to December. In The Gambia, the wet season
is from July to December and the dry season is from January to June. For testing CRP and zinc (Zn2+) levels in plasma, 63 plasma samples were tested from
Malawian infants 3 months post BCG vaccination. Among the plasma samples selected, 6 samples were excluded from CRP testing as these infants were
immunized with DPT, Hib and IPV within 7 days prior to blood collection. The number of samples excluding those who had DPT, Hib and IPV immunization within
7 days before the blood collection is indicated in parentheses.
Hur et al. BMC Infectious Diseases 2014, 14:184 Page 3 of 10
http://www.biomedcentral.com/1471-2334/14/184
Malawi, The Gambia and the UK. Among Malawian infants,
themedian concentrations of IFN-γ, CRP and zinc were com-
pared between infants born in the rainy and dry seasons. The
association between CRP, zinc and cytokines were examined
by calculating the Spearman’s rank correlation coefficient, and
the p values obtained from multiple comparisons were ad-
justed by Bonferroni correction. All of the data obtained from
the multiplex bead assay, zinc and CRP tests were analysed
with values corrected for background production by subtract-
ingmedium alone (negative control) values.
Results
Comparison of infant cytokine/chemokine signatures in
Malawi, the Gambia and the UK
The effect of geographical location on cytokine/chemo-
kine responses to M. tb PPD was examined in Malawian
and Gambian infants. The Gambian infants vaccinated
at birth showed more than twice the median concen-
tration of IFN-γ, IL-1α, IL-1ra, IL-6, TNF-β, TGF-α,
IL-12p70 and RANTES in response to M. tb PPD com-
pared to Malawian infants vaccinated at birth (P < 0.05)
(Figure 1). While there were small differences in median
values of most of the other cytokines, these differences did
not reach significance (P > 0.05) (Figure 1, Additional file 1:
Table S1). The net MCP-1 responses to M. tb PPD and
PHA were very low in Gambian infants, but this was due
to high background levels (Table 2). IL-3, IL-4 and IL-15
were not detected in supernatants from either Malawian or
Gambian infants. When compared to results from UK in-
fants previously tested at 3 months post BCG vaccination,
the Gambian infants showed significantly lower median IFN-
γ, IL-1α, IFN-α2, IL-17, IL-12p40, sCD40L, IP-10, IL-8,
Figure 1 Cytokine response to M. tb PPD in Malawian and Gambian infants vaccinated in the first week of life. The production of IFN-γ
(P = 0.0024), IL-1α (P = 0.0020), IL-1ra (P = 0.0008), IL-6 (0.0002), TNF-β (P = 0.0032), TGF-α (p = 0.0027), IL-12p70 (P = 0.0145), and RANTES (P = 0.0274)
was significantly higher in Gambian infants (n = 24) than Malawian infants (n = 30) while most of the other cytokines measured showed similar
responses (P > 0.05). The median levels of each cytokine are indicated in red (*P < 0.05, **P < 0.01, ***P < 0.001, Mann Whitney test).
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Table 2 The median responses of cytokines to M. tb PPD by timing of vaccination and population
Analyte (pg/mL) Malawi Malawi The Gambia UK Malawi
BCG between 3–11 weeksa BCG at 1 week BCG at 1 week BCG between 3–13 weeksa Early vs late BCG vaccination
n = 40 n = 30 n = 24 n = 28 Fold differenceb P valuec
Pro-inflammatory
IFN-γ 76 36.8 175.5 902 2.1 0.26
IL-2 1.6 4.2 1.6 10 0.4 <0.001
sIL-2R 1400 96.8 117.7 227 14.5 <0.001
IL-1α 1173 45.5 102.3 399 25.8 <0.001
IL-1β 17 22.1 36.7 27 0.8 0.61
IL-1ra 222 29.1 62.1 116 7.6 <0.001
IL-6 954 1149.1 2654.1 1881 0.8 0.069
TNF-α 139 81.3 87.5 111 1.7 0.030
TNF-β 4 1.6 7.7 14 2.5 0.19
IFN-α2 108 1.6 3.6 22 67.5 <0.001
Th2
IL-4 4 1.6 1.6 1.6 2.5 <0.001
IL-5 75 6.8 6.4 4 11.0 <0.001
IL-13 1434 41.6 19.4 47 34.5 <0.001
Th9
IL-9 10 1.6 1.6 1.6 6.3 <0.001
Th17
IL-17 60 7 5.4 26 8.6 <0.001
T cell regulation
IL-10 95 10.6 20 23 9.0 <0.001
T cell activation
IL-12p40 27.5 8.4 6.6 63 3.3 <0.001
IL-12p70 6 1.6 5.5 1.6 3.8 <0.001
Costimulation
sCD40L 186 30.8 18.6 153 6.0 <0.001
Chemokines
IP-10 3758 2517.2 1530.1 12798 1.5 0.006
MIP-1α 64 130.2 93 623 0.5 0.31
MIP-1β 709.5 348.3 300.5 961 2.0 0.019
MCP-1 15000 6381.3 1.6 9816 2.4 0.015
MCP-3 3065 2003 3242 860 1.5 0.004
MDC 2216 499.1 969.8 1415 4.4 <0.001
Gro 2725 2094 1646 936 1.3 0.11
RANTES 1093 330 1543 611 3.3 0.012
Eotaxin 33.5 46.1 33.4 29 0.7 0.001
Fractalkine 253.5 353.9 222.3 272 0.7 0.032
IL-8 14998 14549 8287 15892 1.0 <0.001
Growth factors
GCS-F 19.5 31 90.9 13 0.6 0.99
GM-CSF 717 117.5 127.6 376 6.1 <0.001
IL-3 49 1.6 1.6 1.6 30.6 <0.001
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FGF-2 and IL-7 responses (P < 0.001) (Table 2, Additional
file 1: Table S1).
The effect of season of birth on cytokine/chemokine
signatures
To investigate the seasonal variation in IFN-γ responses
to M. tb PPD observed previously [4], a large panel of 42
cytokines and chemokines were measured in Malawian
infants vaccinated at birth to examine the difference in
immune responses in more detail. IFN-γ, TNF-α and IL-
10 were significantly higher in the infants born in the
dry season (P < 0.05) while Gro (CXCL1) was higher in
the rainy season (P < 0.01) (Figure 2A). The levels of 38
other analytes including 17 cytokines, 10 chemokines
and 11 growth factors were not statistically different be-
tween the two seasons of birth. The samples obtained
Table 2 The median responses of cytokines to M. tb PPD by timing of vaccination and population (Continued)
TGF-α 4.5 1.6 4.1 1.6 2.8 <0.001
FGF-2 111 21.1 35.6 99 5.3 <0.001
Flt-3 L 30.5 4.3 8 17 7.1 <0.001
IL-7 84.5 1.6 1.6 89 52.8 <0.001
EGF 14.5 14.5 11.1 16 1.0 0.99
VEGF 88.5 209.3 233.5 106 0.4 <0.001
PDGF-AA 506.5 179.2 112.4 108 2.8 <0.001
PDGF-AB/BB 381 305.2 801.5 106 1.2 0.92
The median values of most cytokines and chemokines were higher in the infants vaccinated late compared with the infants vaccinated in the first week after birth
in Malawi. In contrast, infants vaccinated within 7 days of birth in Malawi and The Gambia showed comparable median responses to PPD in many of the
cytokines, compared with the Malawian infants who were vaccinated late. IL-15 was not included due to the undetectable levels in all of the infant samples.
aThe data from the Malawian and UK infants vaccinated between 3–13 weeks of life were obtained from a previous study [18]. The median ages of late
vaccinated Malawian and UK infants are 5 and 7 weeks, respectively.
bThe fold differences of each cytokine response to M. tb PPD were calculated by dividing the median values of the Malawian infants with delayed vaccination
(between 3–11 weeks of life) by those of early vaccinated infants (within 1 week of life).
cP values for the median differences of each cytokine response to M. tb PPD between the two groups (Mann Whitney test).
Figure 2 Effect of season of birth on cytokine/chemokine signatures. A. Comparison of cytokine/chemokine signatures between dry and
rainy seasons of birth in 30 Malawian infants. Among the 42 cytokines and chemokines measured, 3 cytokines including IFN-γ, TNF-α and IL-10
were higher in the infants who were born in the dry season compared with those born in the rainy season. Conversely, Gro production was
significantly higher in infants born in the rainy season than in those with dry season of birth. B. Further analysis considering season of birth
between the Malawian (n = 14) and Gambian infants (n = 24) born in the dry season demonstrated that only IL-1α, IL-1ra and IL-6 responses to
M. tb PPD were significantly higher in the Gambian infants (P < 0.05, Mann Whitney test). Other cytokines including IFN-γ responses to M. tb PPD
in Malawian and Gambian infants who were born in the dry season were not significantly different (P > 0.05, Mann Whitney test). The median
responses to M. tb PPD are indicated in red.
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from the Gambian infants were all from infants born in
the dry season, and their cytokine/chemokine signatures
were compared with 14 Malawian infants who were also
born in the dry season. This revealed that only three cy-
tokines, namely IL-1α, IL-1ra and IL-6, were higher in
the 24 Gambian infants compared with the 14 Malawian
infants also born in the dry season (P < 0.05) (Figure 2B),
though with smaller numbers for this comparison the
power to show differences was low. The median IFN-γ
response to M. tb PPD was not significantly different in
Malawian and Gambian infants born in the dry season
(P = 0.31) (Figure 2B). The median IFN-γ response in
Malawian infants was enhanced from 36.8 to 81.1 pg/mL
when the 16 infants born in the rainy season were
excluded compared to 177.5 pg/ml for the Gambian
infants also born in the dry season.
Cytokine/chemokine signatures in Malawian infants
according to time of BCG vaccination
To determine the effect of age at vaccination on immune
responses to M. tb PPD, the cytokine/chemokine signa-
tures were compared between Malawian infants with
early vaccination (within 1 week of birth) and a group of
Malawian infants from the same cohort, studied previ-
ously, who had received BCG vaccination late (between
3 and 11 weeks of life) [18]. IFN-γ production was not
significantly different between early and late vaccinated
infants (Figure 3) while the levels of 25 other cytokine/
chemokine responses were more than two times higher
in the infants vaccinated late compared with those who
had BCG within 1 week of birth (Table 2). Indeed, the
infants vaccinated late showed more than a 5 fold higher
production of 15 cytokines including several growth fac-
tors (P < 0.001) (Table 2). The median concentrations of
three pro-inflammatory cytokines (sIL-2Rα, IL-1α, IFN-
α2), a regulatory T cell cytokine (IL-10), two Th2 cyto-
kines (IL-5, IL-13) and two growth factors (IL-3, IL-7)
were more than 9 times higher in infants vaccinated be-
tween 3 and 11 weeks of life compared with those vacci-
nated early within one week of birth (Table 2, Figure 3).
Plasma concentrations of zinc and CRP in BCG vaccinated
Malawian infants
Plasma concentrations of zinc and CRP were measured to
determine zinc deficiency and the degree of inflammation
in Malawian infants, and to investigate possible associations
with season of birth and cytokine/chemokine signatures.
Zinc deficiency (< 65 μg/dL) was shown in 9.5% (6/63) of
Malawian children. Eight of 57 Malawian infants showed
plasma CRP levels greater than 10 mg/L, while 2 infants
had CRP levels greater than 100 mg/L (Figure 4). The IFN-
γ response to M. tb PPD was higher in infants born in the
dry season (P < 0.001) while the plasma concentrations of
zinc and CRP were unaffected by season of birth in Malawi
(P > 0.05) (Figure 4) although 7 of the 8 Malawian infants
with CRP > 10 mg/L were born in the rainy season.
Spearman’s rank correlation showed no evidence that the
plasma zinc and CRP concentrations were associated with
the IFN-γ responses to M. tb PPD (r = 0.04, P > 0.05 for
CRP; r = 0.20, P > 0.05 for zinc; data not shown). Looking
at the correlation between plasma CRP concentration
and the cytokine/chemokine signatures observed in 17
Malawian infants who had samples for testing of both cul-
ture supernatant and plasma, there was no evidence that
Figure 3 Production of cytokines and growth factors in early vaccinated versus late vaccinated infants. The levels of 6 cytokines (sIL-2Rα,
IL-1α, IFN-α2, IL-5, IL-13, IL-10) and two growth factors (IL-3 and IL-7) were significantly higher with more than 9-fold difference in the infants who
were given BCG between 3 and 11 weeks of life (vaccinated late) compared with those vaccinated within one week of birth (vaccinated early).
The concentrations of IFN-γ and TNF-α were also higher in late vaccinated infants but the fold differences in median responses were moderate
compared with the above 6 cytokines and 2 growth factors. The median levels of each cytokine are indicated in red. The data from late
vaccinated Malawian infants were obtained from the previous study [18] (*P < 0.05, ***P < 0.001, Mann Whitney test).
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any cytokine or chemokine induced by M. tb PPD was as-
sociated with plasma CRP concentration (P > 0.05; data
not shown).
Discussion
This study focused on the evaluation of infant immune
responses at 3 months post BCG vaccination, investigat-
ing potential factors that may affect cytokine/chemokine
signatures in infants from different countries and vacci-
nated at different ages. It has been reported that vari-
ation in resistance to TB and efficacy of BCG may be
influenced by latitude dependent factors such as climate,
exposure to nontuberculous mycobacteria and genetics
[3]. In our comparisons of the immunogenicity of BCG
the geographical location and environment of Malawi
and The Gambia are much closer to each other than
they are to the UK and this corresponds with the simi-
larity of the cytokine/chemokine signatures observed. In
addition, the difference in cytokine/chemokine signa-
tures between Malawian and Gambian infants was partly
due to the season of birth; the difference in median
IFN-γ response in Gambian compared to Malawian in-
fants born in the dry season was not statistically signifi-
cant (P = 0.31). One potential confounder may be the
strain of BCG used for vaccination. It is still unknown
how the immune response can be affected by different
vaccine strains as it may depend on stimulating antigen,
population and assay protocol. In this study, the infants
were not immunised with the same BCG vaccine strains;
Malawian and UK infants were immunized with the
Danish strain, SSI 1331 while Gambian infants received
BCG-Russia. These two strains are genetically different
and have been shown to induce a different immune
response to crude CFP and Ag85 antigens in chil-
dren in Uganda [20,21]. Immunization with BCG-
Denmark or BCG-Japan induced higher frequencies of
mycobacterial-specific polyfunctional and cytotoxic T
cells compared with BCG-Russia in Australia [22].
However, statistical differences were shown only when
BCG was used for in vitro stimulation, and not with
PPD or MTB antigens [22]. In addition, there were no
significant differences in cytokine responses to BCG and
PPD measured in culture supernatant between infants
immunized with BCG-Denmark or BCG Russia [22]. In
our study, production of only 3 of 42 cytokines (IL-1,
IL-1ra and IL-6) was significantly different in the infants
from Malawi and the Gambia after adjusting for season
of birth. Therefore, the differences in cytokine responses
to M. tb PPD between Malawi and The Gambia may be
due to season of birth rather than to the BCG vaccine
strains.
The cytokine/chemokine signatures observed were in-
fluenced by the timing of BCG vaccination. In Malawi,
when compared with infants vaccinated early, the infants
vaccinated later (a median age of 5 weeks) showed
higher responses to M. tb PPD for most cytokines and
chemokines measured but not for IFN-γ. A similar find-
ing of varying BCG immunogenicity by age at vaccin-
ation was reported in South African infants, showing
that enhanced BCG-specific T cell responses were ob-
served in infants when vaccination was delayed from
birth to 10 weeks [23]. However, two studies in The
Gambia [24] and Uganda [25] showed contradicting re-
sults; the magnitude of the IFN-γ response was not sig-
nificantly altered by the timing of vaccination when
comparing infants vaccinated at birth or 2 months in
The Gambia [24], whereas greater frequencies of BCG-
specific IFN-γ positive CD4+ T cells were detected in the
group vaccinated at birth compared with those vacci-
nated at 6 weeks of age in Uganda [25].
In this study, there was no evidence of a difference in
median IFN-γ production between Malawian infants
vaccinated early compared with those vaccinated late,
but there was a trend of higher responses in those vacci-
nated late. The Malawian infants vaccinated late showed
higher median (p < 0.001) Th2 (IL-4, IL-5 and IL-13)
Figure 4 Concentrations of plasma zinc (Zn2+), CRP and IFN-γ in Malawian infants. Zinc deficiency was not detected in the majority of the
Malawian infants although 6 of 63 infants showed zinc deficiency (< 65 μg/dL). Levels of CRP greater than 10 mg/L were detected in 8 Malawian
infants. The median IFN-γ responses to M. tb PPD were different between early vaccinated infants with rainy (n = 40) and dry season (n = 23) of
birth (P < 0.001, Mann Whitney test) while the plasma zinc and CRP concentrations were unaffected by season of birth (P > 0.05, Mann Whitney
test). The median levels of zinc, CRP and IFN-γ are indicated in red.
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recall responses to M. tb PPD than infants vaccinated at
birth. This observation suggests that different immune
signatures develop according to timing of vaccination
which might be an important factor in relation to the in-
duction of protective immune responses following vac-
cination. The samples obtained from early and late BCG
vaccinated infants in Malawi were derived from the
same large cohort study [4]. A total of 615 Infants were
vaccinated with BCG between 2002 and 2004, and blood
samples were obtained from 590 infants at 3 months
post BCG vaccination between 2003 and 2005 [4]. Blood
samples were obtained from 590 of these infants at
3 months post BCG vaccination. Infants were vaccinated
early or late throughout the whole recruiting period.
This was as a result of whether the infants were born in
hospital and vaccinated at birth or born elsewhere and
brought to the clinic later for vaccination. There was no
difference in the vaccination they received. Thus no
other confounding factors that might be associated with
delayed vaccination have been identified. The results of
this study are also consistent with evidence that new-
borns can develop Th1 responses following BCG vaccin-
ation [24,25] unlike the Th2 bias in mice [26].
In terms of the proportion of infants who showed greater
than 10 mg/L of CRP in their plasma, the majority (7/8)
were born in the rainy season. In the whole infant cohort
no infants showed helminth infections at 3–6 months of
age. No infants were bled if unwell or with symptoms of
malaria or other infection. We excluded the infants whose
mothers had HIV, malaria, or helminth infections but we
did not test for other diseases which could induce inflam-
mation in the infants and might affect the CRP concentra-
tion in the infants and their mothers. Therefore higher
plasma CRP concentration, reflecting level of inflammation,
most likely indicates a higher burden of infections, but
there was no association between the IFN-γ responses to
M. tb PPD and CRP concentration (data not shown). Most
of the Malawian infants had a normal range of plasma zinc
concentrations and none of the cytokines tested were asso-
ciated with the concentration of zinc (data not shown), in-
dicating that zinc status might not be a major factor
affecting the differences in infant immune responses in
Malawi, at least when measured at 3 months post BCG
vaccination.
To examine if cytokine activity had been lost over time
in storage, we tested culture supernatant samples which
had been collected from 4 infants at 3 years post BCG
vaccination and stored in the same place as the archived
samples we used for this study, since 2006. There was
no significant difference in IFN-γ concentrations of 19
culture supernatant samples from each of 4 subjects
when measured in 2006 and again in 2010, and a strong
correlation was found between IFN-γ values obtained in
2006 and 2010 (r = 0.9808, P < 0.0001) [27].
Differences in the infant immune responses to M. tb
PPD following BCG vaccination are documented at dif-
ferent latitudes and in different populations. The extent
to which these influence BCG efficacy remains to be
evaluated alongside studies looking for correlates of pro-
tection against TB [28]. Season of birth and timing of
vaccination have been shown here to be critical factors
affecting the cytokine/chemokine signatures induced by
BCG vaccination in Malawian infants. In addition, this
study indicates the potential importance of the balance
between type 1 and 2 cytokines, or between pro- and
anti-inflammatory cytokines rather than the absolute
quantities of a particular cytokine. Although we were
limited by the number of samples tested, the results of
this study suggest the need for additional biomarkers to
be measured in conjunction with IFN-γ to assess the im-
munogenicity of BCG, and that potential factors affect-
ing immune responses following vaccination such as
season of birth should be taken into account for future
trials of new TB vaccines.
Conclusions
In conclusion, variation in geographical location, season of
birth, and age at vaccination may alter the cytokine/chemo-
kine signature to M. tb PPD, in infants at 3 months post
BCG vaccination, while the concentration of plasma zinc or
CRP did not correlate with the cytokine/chemokine signa-
ture to M. tb PPD. We therefore recommend that the sea-
son of birth and timing of priming vaccines, as well as
geographical setting, should be considered in the design of
clinical trials of new TB vaccines.
Additional file
Additional file 1: Table S1. The fold differences of each cytokine
response to M. tb PPD between Gambian and Malawian infants, Gambian
and UK infants. The cytokine responses to M. tb PPD were compared
among Malawian and Gambian infants who were vaccinated at 1 week
after birth, and UK infants vaccinated between 3-13 weeks of life [18].
d,f The fold differences of each cytokine response to M. tb PPD were
calculated by dividing the median values of Gambian infants by Malawian
infants with early vaccination and by dividing the median values of UK
infants by those of Gambian infants, respectively. eP values for the
median differences of each cytokine response to M. tb PPD between the
two groups (Mann Whitney test).
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